While there are no FDA-approved drugs for lupus nephritis, standard treatment includes high-dose corticosteroids and immunosuppressive drugs. These therapies have many toxic side effects and as many as 50% – 75% of patients don’t respond to treatment. The majority of individuals who respond to treatment go on to relapse within 5 years.
The CD6-ALCAM signaling pathway plays a central role in the modulation of effector T cells, or Teff cells. Teff cells are thought to play a central role in multiple autoimmune diseases including lupus nephritis.
Learn more about the CD6-ALCAM Pathway and its role in immune-inflammatory diseases